Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 30;17(11):932-939.
doi: 10.6026/97320630017932. eCollection 2021.

Comparative molecular docking and simulation analysis of molnupiravir and remdesivir with SARS-CoV-2 RNA dependent RNA polymerase (RdRp)

Affiliations

Comparative molecular docking and simulation analysis of molnupiravir and remdesivir with SARS-CoV-2 RNA dependent RNA polymerase (RdRp)

Shashank M Patil et al. Bioinformation. .

Abstract

Treatment of SARS-CoV-2 targeting its RNA dependent RNA polymerase (RdRp) is of current interest. Remdesivir has been approved for the treatment of COVID-19 around the world. However, the drug has been linked with pharmacological limitations like adverse effects and reduced efficiency. Nevertheless, recent advancements have depicted molnupiravir as an effective therapeutic agent to target the SARS-CoV-2 RdRp. The drug has cleared both in vitro and in vivo screening. It is in phase-III clinical trial. Nonetheless, there are no data on themolecular binding interaction of molnupiravir with RdRp. Therefore, it is of interest to report the binding interaction of molnupiravir using molecular docking. It is also of interest to show its stability during interaction using molecular dynamics and binding free energy calculations along with drug likeliness and pharmacokinetic properties in comparison with remdesivir.

Keywords: Molnupiravir; RdRp; Remdesivir; SARS-CoV-2; binding free energy calculations; druglikeliness; in silico experiments; molecular docking; molecular dynamics; pharmacokinetic properties.

PubMed Disclaimer

Conflict of interest statement

No conflicts of interest associated with this work.

Similar articles

Cited by

References

    1. Patil SM, et al. Biomed. Pharmacol. J. . 2020
    2. {'text': '', 'ref_index': 2, 'ids': [{'type': 'DOI', 'value': '10.13005/bpj/2033', 'is_inner': False, 'url': 'https://doi.org/10.13005/bpj/2033'}]}
    1. Kumari VC, et al. Int. J. Pharm. Pharm. Sci. . 2020;12:1.
    2. {'text': '', 'ref_index': 2, 'ids': [{'type': 'DOI', 'value': '10.22159/ijpps.2020v12i8.38206', 'is_inner': False, 'url': 'https://doi.org/10.22159/ijpps.2020v12i8.38206'}]}
    1. Patil SM, et al. J. Biomol. Struct. Dyn. . 2021 - PubMed
    1. Painter GR, et al. Curr. Opin. Virol. . 2021;50:17. - PMC - PubMed
    1. Holman W, et al. Trials. . 2021;22:561. - PMC - PubMed

LinkOut - more resources